STOCK TITAN

iBio, Inc. - IBIO STOCK NEWS

Welcome to our dedicated page for iBio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on iBio stock.

iBio, Inc. (symbol: IBIO) is a specialized contract development and manufacturing organization (CDMO) that facilitates the journey from early product selection to market launch. Situated within the healthcare sector, iBio is renowned for its plant-based protein expression technologies, which are pivotal in developing vaccines, therapeutic proteins, and biopharmaceutical products.

The company operates through two primary segments: Biopharmaceuticals and Bioprocessing. iBio's Biopharmaceuticals segment focuses on the development and commercialization of product candidates aimed at addressing critical health issues such as fibrotic diseases, cancers, and infectious diseases. The Bioprocessing segment, meanwhile, involves comprehensive manufacturing and regulatory support services offered through iBio CDMO.

iBio's technology platform and state-of-the-art facilities are designed to expedite development processes, providing significant time and cost advantages over traditional approaches. The company boasts a team of skilled protein scientists, microbiologists, manufacturing experts, and regulatory professionals committed to delivering seamless scale-up from preclinical to commercial production.

Recent achievements include advancements in biotherapeutics and diagnostic products, showcasing iBio's capability to innovate and respond to global health challenges effectively. The company also maintains strategic partnerships that bolster its research and development efforts, ensuring consistent progress in the healthcare landscape.

With its focus on rapid manufacturing support and regulatory compliance, iBio stands out as a reliable partner for clients seeking efficient pathways to clinical and commercial success.

Rhea-AI Summary

iBio, Inc. (NYSEA: IBIO) announced the pricing of an underwritten public offering of 3,365,385 shares at $1.04 each, with Series A and B warrants included. The offering aims to raise approximately $3.5 million for operating costs, particularly for research, development, and general corporate expenses, including employee payments. The closing is anticipated on or about December 9, 2022. Additionally, the underwriter has a 30-day option to purchase extra shares and warrants. This follows the company's effective shelf registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-58.13%
Tags
-
Rhea-AI Summary

iBio announced plans to conduct an underwritten public offering of common stock and Series A and B warrants, with a potential 30-day underwriter option for additional shares. The proceeds are aimed primarily at operating costs, including research and development and general corporate purposes. The offering, which is subject to market conditions, is associated with a shelf registration statement previously filed. H.C. Wainwright & Co. leads the offering management. iBio aims to strengthen its financial position while focusing on antibody development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-58.13%
Tags
-
Rhea-AI Summary

iBio, Inc. (NYSE: IBIO) announced that its Chief Scientific Officer, Martin Brenner, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 1:20 p.m. Eastern Time. The event will be broadcast live and archived on the company's website under the 'News & Events' section. iBio specializes in developing next-generation biopharmaceuticals utilizing computational biology to enhance antibody therapies for difficult-to-treat cancers and diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences
Rhea-AI Summary

iBio, Inc. (NYSE: IBIO) announced its participation in the Antibody Engineering & Therapeutics Conference 2022 in San Diego, presenting two posters highlighting applications of its AI-driven RubrYc Discovery Engine.

The presentations include AI-Designed Structural Immunogens targeting PD-1 Agonist and EGFRvIII tumor-specific epitopes. Additionally, they will showcase identification efforts of a potent PD-1 Agonist antibody and a targeted approach for tumor cells. The RubrYc Discovery Engine aims to develop effective immunotherapies for challenging cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
News
Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) announces the immediate resignation of CEO Thomas F. Isett from both the Board of Directors and his executive duties. The current Chair, William (Chip) Clark, will oversee the leadership team during the search for a new CEO. Isett's contributions included enhancing iBio's portfolio and acquiring RubrYc’s drug discovery engine. The company emphasizes its commitment to developing innovative antibody treatments and maintaining its operations amidst leadership changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) is divesting its contract development and manufacturing organization (CDMO) to focus on immuno-oncology assets and AI-driven drug discovery. This restructuring is expected to yield approximately 50% in annualized cost savings, reducing monthly expenses by $2.5-3.0 million. The divestiture process is aimed at advancing lead candidates like IBIO-101 and optimizing their proprietary technology, with expectations to complete the sale in 2023, contributing to a cash runway into mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.71%
Tags
none
Rhea-AI Summary

iBio has provided its preliminary unaudited financial results for the fiscal year ending June 30, 2022, reporting revenues of approximately $2.4 million, a slight increase of 1% from fiscal 2021. The company recorded a net loss of $50.3 million, expanding by $27.1 million due to rising R&D and administrative expenses. In a strategic move, iBio acquired assets from RubrYc Therapeutics, enhancing its immunotherapy portfolio. However, it has opted not to proceed with the IND submission for its COVID-19 vaccine candidate IBIO-202.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.38%
Tags
-
Rhea-AI Summary

iBio announced the acquisition of RubrYc Therapeutics to enhance its immuno-oncology pipeline and AI-driven drug discovery capabilities. The acquisition includes a patented AI Drug Discovery Platform and rights to two previously licensed drug candidates, with an upfront payment of $1 million in stock. Potential development milestones of up to $5 million are also available. iBio aims to extend its cash runway and will discuss its strategic transformation and FY2022 results in a conference call on September 27, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
-
Rhea-AI Summary

iBio, Inc. announced successful completion of its first batch of a proprietary nucleocapsid antigen for the vaccine candidate IBIO-202 under cGMP conditions. This new vaccine aims to provide long-lasting protection against COVID-19 variants through the nucleocapsid protein, rather than the spike protein used in current vaccines. The company is analyzing data from its challenge studies to further validate this approach. iBio is actively pursuing funding opportunities with Congress to support next-generation COVID-19 vaccine development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
covid-19
Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company is known for its innovative FastPharming® Manufacturing System for biopharmaceuticals. A pre-recorded presentation will be available on demand for registered attendees starting May 24, 2022, and can also be accessed on iBio's website under 'News & Events'. iBio focuses on developing biopharmaceuticals for cancer, fibrotic, and infectious diseases, leveraging its state-of-the-art manufacturing capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
conferences

FAQ

What is the current stock price of iBio (IBIO)?

The current stock price of iBio (IBIO) is $2.48 as of December 20, 2024.

What is the market cap of iBio (IBIO)?

The market cap of iBio (IBIO) is approximately 22.2M.

What does iBio, Inc. specialize in?

iBio specializes in plant-based protein expression technologies for developing vaccines, therapeutic proteins, and biopharmaceutical products.

What are the main segments iBio operates in?

iBio operates in two main segments: Biopharmaceuticals and Bioprocessing.

What services does iBio offer?

iBio offers comprehensive development and manufacturing services, from early product selection to regulatory approval and commercial product launch.

Who comprises iBio’s team?

iBio's team includes knowledgeable protein scientists, microbiologists, and experts in manufacturing and regulatory affairs.

What are the key areas iBio's products target?

iBio's products target fibrotic diseases, cancers, and infectious diseases.

How does iBio's technology platform benefit clients?

iBio's technology platform provides significant time and cost advantages, enabling rapid development and seamless scale-up from preclinical to commercial production.

What recent achievements has iBio made?

iBio has made advancements in biotherapeutics and diagnostic products, showcasing its innovative capabilities.

What is iBio CDMO?

iBio CDMO is the division of iBio that handles bioprocessing activities, offering manufacturing and regulatory support.

Does iBio collaborate with other organizations?

Yes, iBio maintains strategic partnerships to enhance its research and development efforts.

How can I contact iBio for investor or media relations?

You can contact Stephen Kilmer for investor relations at skilmer@ibioinc.com or Susan Thomas for media relations at susan.thomas@ibioinc.com.

iBio, Inc.

NYSE:IBIO

IBIO Rankings

IBIO Stock Data

22.23M
9.14M
0.14%
31.49%
2.52%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK